Satellos Bioscience Inc · TSX:MSCL

Satellos Bioscience — Investor Presentation (February 2023)

21 slides from Satellos Bioscience's investor presentation, February 2023

  1. Slide 1: Satellos Bioscience Inc. Non-Confidential Overview

    Slide 1: Satellos Bioscience Inc. Non-Confidential Overview

    FEBRUARY 2023 SATELLOS BIOSCIENCE INC. NON-CONFIDENTIAL OVERVIEW Omnis cellula e cellula Rudolph Virchow c.1858 1

  2. Slide 2: Legal Disclaimers

    Slide 2: Legal Disclaimers

    2 Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or perfor

  3. Slide 3: Satellos: Revolutionizing the treatment of muscle disorders

    Slide 3: Satellos: Revolutionizing the treatment of muscle disorders

    3 Satellos: Revolutionizing the treatment of muscle disorders  Pivotal Discoveries  Signaling role for dystrophin in muscle stem cells1  Dystrophin drives polarity and regeneration in Duchenne muscular dystrophy  Pathways which can be modulated with drug to restore polarity and regeneration  De

  4. Slide 4: Dystrophin's role in stem cells outweighs role in fibers

    Slide 4: Dystrophin's role in stem cells outweighs role in fibers

    4 Dystrophin’s role in stem cells outweighs role in fibers Orthodox view: Satellos discovery: Dystrophin in fibers provides structure Dystrophin in stem cells drives regeneration 2x10-12 Dystrophin expressed in Dystrophin expressed in muscle fibers muscle stem cells Orthodox solution: genetic therap

  5. Slide 5: Refresher: How muscle stem cell polarity drives regeneration

    Slide 5: Refresher: How muscle stem cell polarity drives regeneration

    5 Refresher: How muscle (satellite) stem cell polarity drives regeneration Normal Stem Cell: Duchenne Stem Cell: Polarity and Regeneration Enabled Polarity and Regeneration Impaired Muscle fiber Muscle fiber 2x10-12 N S Par1b Dystrophin Return to quiescence Basal lamina Basal lamina Polarity and reg

  6. Slide 6: 3rd party evidence supports Satellos approach

    Slide 6: 3rd party evidence supports Satellos approach

    6 3rd party evidence supports Satellos approach 2010  Clinicians observe elevated stem cells in Duchenne patients  Supports thesis of deficit in asymmetric divisions  Significance not understood at the time 2016  Kunkel group identifies Dystrophin null escaper dogs  Regeneration implicated but

  7. Slide 7: Target and Proof of Concept

    Slide 7: Target and Proof of Concept

    Target and Proof of Concept: • Identified kinase (codenamed ‘K9) as polarity ‘switch’ • Rapid effect on muscle regeneration with drug treatment • Linear dose response in force generation 7

  8. Slide 8: IP Landgrab: novel screening platform identified polarity regulators

    Slide 8: IP Landgrab: novel screening platform identified polarity regulators

    IP Landgrab: Satellos’ novel screening platform identified polarity regulators Input Output Targets Curated siRNA Library Targets affecting polarity Priority Pathway MyoReGenXTM NOTCH (via K9*) * * Identified Notch/K9 as capable of rescuing polarity in Mdx * Codename

  9. Slide 9: "K9" an appealing, druggable target

    Slide 9: "K9" an appealing, druggable target

    9 “K9” an appealing, druggable target Known Protein Under Development in “K9” Human Safety “K9” Role in Muscle Different Disease Area Profile Stem Cells “K9”  Two Phase 1 studies  Symmetric division  Not previously pursued in Duchenne  no serious adverse  modulation of Notch models to best of o

  10. Slide 10: POC (study #1): Progenitor Cells

    Slide 10: POC (study #1): Progenitor Cells

    10 POC (study #1): “K9” inhibition with drug rapidly shows effect on polarity On mechanism Experimental Design Drug* Day 0 Day 17 (No. Myog+ per mm2) (No. Pax7+ per mm2) Progenitor Cells Stem Cells Four doses given intermmitently Mdx mice Analysis n = 5/group Control Drug Control Drug Stem cells Pro

  11. Slide 11: Striking effect on progenitors and regeneration capacity

    Slide 11: Striking effect on progenitors and regeneration capacity

    11 Striking effect on progenitors and regeneration capacity Control Drug Treated Myogenin expression, a marker for progenitors, corresponds to areas of focal damage Pax7 is a marker for stem cells | Myogenin for progenitors

  12. Slide 12: Significant regeneration of muscle c. 40%

    Slide 12: Significant regeneration of muscle c. 40%

    12 Significant regeneration of muscle c. 40% (NB., each image is from the TA muscle of a separate Mdx mouse) Control Drug Treated 12

  13. Slide 13: POC (study #2): Rapid increase in muscle force

    Slide 13: POC (study #2): Rapid increase in muscle force

    13 POC (study #2): Rapid increase in muscle force in dose dependent manner Study 2: Similar design to study 1, 3 dose groups, n=7 per group We estimate mdx strength to be roughly 70% of normal at this age suggesting muscle strength is being restored to near normal capacity with only two weeks of dru

  14. Slide 14: Status and Plan: Chemistry, Timeline, Budget

    Slide 14: Status and Plan: Chemistry, Timeline, Budget

    Status and Plan: Chemistry, Timeline, Budget 14

  15. Slide 15: Novel chemical matter

    Slide 15: Novel chemical matter

    15 Novel chemical matter: Three series developed by AI/ML and de-novo design SERIES A SERIES B/C Lead Compound Series Back-up/Second Compound Series  Nanomolar potency  Picomolar potency  ADME, PK, and Kinome selectivity  Advanced SAR/optimization ongoing  Activity in Mdx models  Selectivity p

  16. Slide 16: Satellos timeline: Strong value catalysts over next months

    Slide 16: Satellos timeline: Strong value catalysts over next months

    16 Satellos timeline: Strong value catalysts over next 18 months Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Lead program - Duchenne SAT-3153 Phase I completed Lead Compound CMC IND-enabling Studies FDA submission  Pre-IND meeting with FDA  POC development in other disease areas  Additional philanthropic

  17. Slide 17: Lead Development Program in Place

    Slide 17: Lead Development Program in Place

    17 Lead Development Program in Place CMC IND-Enabling Studies Clinical  Relationship with provider  Study slots secured with CRL  Phase 1 established  analytical validation  Healthy volunteers  general toxicology  Phase 2  Simple, cost-effective synthetic  small & large species  In talks w

  18. Slide 18: Corporate: Cap Table, Team

    Slide 18: Corporate: Cap Table, Team

    Corporate:  Cap Table  Team 18

  19. Slide 19: Background and Cap Table

    Slide 19: Background and Cap Table

    19 Background and Cap Table BACKGROUND CAPITAL TABLE  Founded 04/2018 by repeat players Common Shares 41,800,000 Warrants 5,300,000  RTO on TSX.V on 08/13/2021 Stock options 4,000,000  CDN$18m raised cumulatively Fully Diluted 51,100,000  Venture philanthropy partner Insiders: ~27% (fully dilute

  20. Slide 20: Experienced Board and Scientific Excellence

    Slide 20: Experienced Board and Scientific Excellence

    Experienced Board 20 Geoffrey Mackay Adam Mostafa Rima Al-awar, PhD William McVicar, PhD William Jarosz, JD Frank Gleeson, MBA Chair — Board of Directors Chair – Audit Committee Board Member Board Member & Advisor CEO – AmpB Technologies Inc. Co-Founder & CEO  Founder and CEO -  CFO - X4  Head –

  21. Slide 21: Thank You!

    Slide 21: Thank You!

    THANK YOU! SATELLOS BIOSCIENCE INC. Rebuilding muscle from within TM Satellos Bioscience Inc. | Att’n: Frank Gleeson, CEO 79 Wellington Street West, 33rd Floor, Toronto, Ontario M5K 1N2 21 647-660-1780 | info@satellos.com

Source: Internet Archive copy of satellos.com

More decks from Satellos Bioscience Inc

All 17 Satellos Bioscience decks